Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
1992 2
1993 1
1999 1
2000 1
2001 2
2002 1
2005 1
2006 1
2007 2
2008 2
2009 1
2012 1
2013 1
2014 2
2015 1
2016 2
2017 4
2018 3
2019 2
2020 8
2021 2
2022 3
2023 10
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. Among authors: saltzstein dr. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.
Reply by Authors.
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM. Jani AB, et al. Among authors: saltzstein d. J Urol. 2023 Aug;210(2):310-311. doi: 10.1097/JU.0000000000003493.02. Epub 2023 Jul 7. J Urol. 2023. PMID: 37416959 No abstract available.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Jani AB, et al. Among authors: saltzstein d. J Urol. 2023 Aug;210(2):299-311. doi: 10.1097/JU.0000000000003493. Epub 2023 Apr 26. J Urol. 2023. PMID: 37126069
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. Steinberg GD, et al. Among authors: saltzstein d. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. Future Oncol. 2024. PMID: 38189180
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Shore ND, et al. Among authors: saltzstein dr. Adv Ther. 2023 Nov;40(11):4919-4927. doi: 10.1007/s12325-023-02634-7. Epub 2023 Sep 15. Adv Ther. 2023. PMID: 37713020 Free PMC article. Clinical Trial.
53 results